Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia



Status:Terminated
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:40 - 90
Updated:4/26/2017
Start Date:October 2014
End Date:March 6, 2017

Use our guide to learn which trials are right for you!

A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia

Study to Evaluate the Efficacy and Safety of AMG0001 in Subjects with Critical Limb
Ischemia.

This is a double-blind, randomized, placebo-controlled, phase 3, multinational, multicenter
study of AMG0001 (HGF plasmid) in subjects with Critical Limb Ischemia (CLI).

Inclusion Criteria:

1. Subjects with CLI (Severe Rutherford 4 and Rutherford 5) who have:

- No option for revascularization by endovascular intervention or surgical bypass

or

- Poor option (high risk) for revascularization by surgery and no option for an
endovascular intervention (see Section 3.1 Study Population for full definition
for appropriate inclusions).

2. Subjects 40-90 years of either gender who have signed an informed consent form either
directly or through a legally authorized representative.

3. Subjects currently are taking a statin and an anti-platelet agent (e.g., clopidogrel,
ticlopidine, aspirin, etc.) for 2 weeks or more prior to Day 0 as part of their
standard of care, unless contraindicated. Subjects for whom these agents are
contraindicated will have the reason for contraindication recorded in their case
report form (CRF).

4. If female, the subjects must not be of child bearing potential, e.g., post-menopausal
or surgically sterile.

5. If a male subject is of reproductive potential, he must agree to use an accepted and
effective (barrier) form of birth control starting with the first dose of study
product and continue for 12 weeks from the last dose of study product. This applies
to both courses of treatment.

6. Subjects with a previous medical history of myocardial infarction and/or stroke
should have adequate management of risk factors to prevent secondary occurrence. (See
Section 4.2 Medical History for guidelines on appropriate secondary prevention.)

7. Subjects should have the ability to understand the requirements of the protocol and
agree to return for the required study visits, assessments and follow up.

- The index leg will be the leg with the greater severity of CLI disease. Entry
requirements apply to the index leg. The index leg may also be referred to as
the treated leg or affected leg in the text of this protocol or other study
documents. If the subject has two legs that have the same Rutherford
classification (severe Rutherford 4 or Rutherford 5) and are both eligible for
treatment, the leg with greater disease severity (based on more extensive
necrosis or more extensive/deeper ulceration(s), difference in ABI or TBI ≥ 0.1,
and/or more extensive vascular disease based on the angiogram) will be chosen as
the index leg. If there is no clinical, hemodynamic or angiographic or other
evidence to determine which leg has greater disease severity, the subject will
be excluded from the study.

- These entry criteria will be enforced (prior to randomization) by the Sponsor,
as well as an Entry Committee who will review all relevant clinical data
including but not limited to medical illness, CLI status, the findings of an
angiogram, ulcer photographs and measurements and hemodynamic data.

Exclusion Criteria:

1. Subjects whose CLI status is unstable (spontaneous marked improvement or marked
worsening during the screening period) or who have excessive tissue necrosis that is
unlikely to benefit from medication, or those poor option subjects requiring
immediate revascularization by surgery. Stability of the CLI status will be confirmed
by the Principal Investigator prior to randomization and retrospectively reviewed by
the Adjudication Committee.

2. Subjects who may require a major amputation (amputation at or above the ankle) within
4 weeks of Day 0 (± 4 weeks of Day 0).

3. Subjects with ulcers with exposure of tendons, osteomyelitis or uncontrolled
infection or with the largest ulcer that is greater than 20 cm2 in area (>10 cm2 area
if on the heel).

4. Subjects with purely neuropathic, or with venous ulcers.

5. Subjects in Rutherford 6 class.

6. Subjects who have had revascularization by surgery or angioplasty within 3 months,
unless the procedure has failed based on the anatomy or the hemodynamic measurements.

7. Subjects with a diagnosis of Buerger's disease (Thrombo-angiitis Obliterans).

8. Subjects currently receiving immunosuppressive, chemo or radiation therapy.

9. Evidence or history of malignant neoplasm (clinical, laboratory or imaging) except
for successfully excised basal cell or squamous cell carcinoma, or successfully
excised early melanoma of the skin. Subjects, who had successful tumor resection or
radio-chemotherapy of breast cancer more than 10 years prior to inclusion in the
study, and with no recurrence, may be enrolled in the study. Subjects, who had
successful tumor resection or radio-chemotherapy of all other tumor types and have
been in remission for more than 5 years prior to inclusion in the study, and with no
recurrence, may be enrolled in the study. A dermatological exam will have ruled out
any skin cancer.

10. Subjects who have proliferative retinopathy, or moderate or severe non-proliferative
retinopathy, from any cause (ETDRS Score > 35), clinically significant macular oedema
or previous panretinal photocoagulation therapy (Results from the Early Treatment
Diabetic Retinopathy Study. Ophthalmology May 1991 Supplement 98: 823-833).

11. Females of child-bearing potential defined as subjects that are not surgically
sterile or post-menopausal.

12. Subjects with severe renal disease defined as significant renal dysfunction evidenced
by an estimated creatinine clearance of <30 mL/minute (calculated using the Cockroft
Gault formula), or receiving chronic hemodialysis therapy.

13. Any co-morbid condition likely to interfere with assessment of safety or efficacy
endpoints, acute cardiovascular events (i.e., CVA, MI, etc.) within 3 months of
treatment, or any disease that in the opinion of the Investigator may result in
subject mortality in less than 3 months.

14. Subjects with known liver disease (e.g., hepatitis B or C or cirrhosis of the liver).

15. A subject with HIV, AIDS, severe uncontrolled inflammatory disease or severe
uncontrolled autoimmune disease (e.g., ulcerative colitis, Crohn's disease, etc).

16. Subjects who have a significant psychiatric disorder or mental disability that could
interfere with the subject's ability to provide informed consent or comply with study
procedures.

17. Subjects with a current, uncorrected history of alcohol or substance abuse.

18. Diabetic subjects with an uncorrected HbA1c > 9.0% during the screening period.

19. Subjects that have been administered rhPDGF (e.g, becaplermin) or other growth
factors locally within one month of randomization.

20. Subjects who have received another investigational drug within 30 days of
randomization or have previously received any gene transfer therapy within 3 years of
entering the study.
We found this trial at
29
sites
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Richard J. Powell, MD
Phone: 603-650-6379
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Luke Brewster, MD
Phone: 404-778-4920
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
72 East Concord Street
Boston, Massachusetts 02118
(617) 638-5300
Principal Investigator: Jeffrey Siracuse, MD
Phone: 617-414-6839
Boston University School of Medicine A leader in medical education and research, Boston University School...
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Mark Wyers, MD
Phone: 617-632-9228
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Adam Beck, MD
Phone: 352-273-7598
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Gregory Landry, MD
Phone: 503-494-6238
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Thomas Brothers, MD
Phone: 843-792-5935
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Karen Ho
Phone: 312-695-3264
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Edegem, 2650
Principal Investigator: Jeroen Hendriks, MD
Phone: 0318213785
?
mi
from
Edegem,
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Eric Peden, MD
Phone: 713-441-9394
?
mi
from
Houston, TX
Click here to add this to my saved trials
Kansas City, Missouri 64111
Principal Investigator: Keith Allen, MD
Phone: 816-982-6122
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Kansas City, Missouri 64116
Principal Investigator: Karl Stark, MD
Phone: 816-842-5555
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
La Jolla, California 92093
Principal Investigator: Dennis F. Bandyk, M.D
Phone: 858-657-1299
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Laguna Hills, California 92653
Principal Investigator: Kenneth B. Deck, MD
Phone: 949-680-3490
?
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Little Rock, Arkansas 72205
Principal Investigator: Mohammed Moursi, MD
Phone: 501-257-6906
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Roman Nowygrod, MD
Phone: 212-342-4102
?
mi
from
New York, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15240
Principal Investigator: Edith Tzeng, MD
Phone: 412-360-3653
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rome, Georgia 30165
Principal Investigator: Billy G. Chacko, MD
Phone: 706-236-6321
?
mi
from
Rome, GA
Click here to add this to my saved trials
Saint Louis, Missouri 63141
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salisbury, Maryland 21801
Principal Investigator: Douglas Wilhite, MD
Phone: 410-543-7019
?
mi
from
Salisbury, MD
Click here to add this to my saved trials
San Francisco, California 94121
Principal Investigator: Warren J. Gasper, MD
Phone: 415-750-2115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Sarasota, Florida 34239
Principal Investigator: Russell H. Samson, MD
Phone: 941-917-1211
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Sioux Falls, South Dakota 57104
Principal Investigator: Patrick Kelly, MD
Phone: 605-312-7300
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Springfield, Missouri 65807
Principal Investigator: Jon Reese, MD
Phone: 417-820-9587
?
mi
from
Springfield, MO
Click here to add this to my saved trials
Teaneck, New Jersey 07666
Principal Investigator: John H. Rundback, MD
Phone: 201-530-7968
?
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Tucson, Arizona 85745
Principal Investigator: Scott S. Berman, MD
Phone: 520-872-6972
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tulsa, Oklahoma 74104
Principal Investigator: Blebea John, MD
Phone: 918-634-7500
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Winfield, Illinois 60190
Principal Investigator: Michael J. Verta, MD
Phone: 630-933-4487
?
mi
from
Winfield, IL
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
Principal Investigator: Justin Hurie, MD
Phone: 336-716-3296
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials